Europe Iodinated Contrast Media in Interventional X-ray Market – Industry Trends and Forecast to 2030

Europe Iodinated Contrast Media in Interventional X-Ray Market Analysis and Size

The Europe iodinated contrast media in interventional X-Ray market is anticipated to witness huge growth during the forecast period. Every year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and more than 1.8 million deaths in the Europe. The occurrence of chronic conditions with multiple comorbidities is more among older adults. Increasing preference towards iodinated contrast media from traditional contrast media is increasing the market during the forecast period 2023-2030.

Data Bridge Market Research analyses a growth rate in the Europe iodinated contrast media in interventional X-Ray market in the forecast period 2023-2030. The expected CAGR of Europe iodinated contrast media in interventional X-Ray market is tend to be around 5.40% in the mentioned forecast period. The market was valued at USD 714.8 million in 2022, and it would grow upto USD 1088.7 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Europe Iodinated Contrast Media in Interventional X-Ray Market Scope and Segmentation

Market Definition

Iodinated contrast media in interventional X-ray is important for healthcare practitioners make appropriate clinical and diagnostic decisions across numerous levels of health care services. Iodinated contrast media are the type of contrast agents that contain iodine atoms which are used for x-ray-based imaging modalities such as computed tomography (CT). They can also used in fluoroscopy, angiography and venography, and even rarely, plain radiography. It is used for procedures that involves X-rays, such as CT, coronary angiography, angiography, arthrography, myelography and gastrointestinal fluoroscopic studies. Gadolinium contrast agents are used for MRI studies.

Europe Iodinated Contrast Media in Interventional X-Ray Market Dynamics

Drivers

• Higher Demand of Hospitals

The growing demand of hospitals increase the market growth rapidly. Most of the chronic disease diagnostics are majorly carried out in hospitals as they are very complex in nature and it requires technologically advanced products and therefore this is boosting the market for hospital or clinical laboratories.

• Increasing Rate of Complex Comorbidities

The growing occurrence of complex comorbidities and long-term diseases has led to an upsurge in diagnostic imaging tests involving ultrasound, X-rays, and advanced imaging technology such as MRI & CT scans. For instance, GE Healthcare received the U.S. FDA approval for Clariscan, which is a contrast agent used for macrocyclic MRI in November 2019. These products aid in the identification of the need for perioperative scans before surgeries and treatment in interventional procedures which further boost the market growth.

Opportunities

• Rise in Chronic Diseases

The occurrence of chronic conditions with multiple comorbidities is higher among the elderly adults. Every year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and more than 1.8 million deaths in this region. CVD accounts for 45% of all deaths in Europe and around 37% of all deaths in the EU. In 2015, it has been recorded that more than 85 million people in Europe were suffering from CVD and nearly 49 million people were living with CVD in the EU. Thus, this factor create more opportunity for the market growth.

• Increased Drug Approvals

Numerous FDA approval for iodinated contrast agent will also increase the commercialization of new iodinated products in the market. As a result, large number of approvals for iodinated agents will aid in the growth of iodinated contrast media in interventional X-Ray market.  For instance, the Food and Drug Administration (FDA) approved GE Healthcare Visipaque (iodixanol) imaging agent in March 2017. Therefore, growing drug approvals boost the growth of the market.

Restraints/Challenges

• High Cost

The increased expenditure which is required for setting up these techniques hamper the market growth. Numerous market players make huge investments in manufacturing new and advanced machines to increase the process and the cost is increased. Thus, this factor impede the market growth.

This Europe iodinated contrast media in interventional X-Ray market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe iodinated contrast media in interventional X-Ray market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Europe Iodinated Contrast Media in Interventional X-Ray Market

During the pandemic, all diagnostic procedures except COVID diagnosis showed a dip in 2020 which largely affected the growth of the market. Diagnosis of heart diseases reduced by nearly two-thirds globally during the early months of the pandemic as countries and patients prioritized COVID-19. In the post pandemic era, the introduction of digital solutions for precise and effective management of contrast agent injection is projected to boost market growth. Numerous studies are showing the fatal effect of COVID on health that causes heart attacks and strokes; this might surge the market growth in the future.

Recent Developments

• In 2019, General Electric and Daiichi Sankyo Company participated into an agreement that Daiichi Sankyo to transfer the authorization of marketing rights for four diagnostic imaging agents in Japan to GE Healthcare. After completing this agreement, the company expanded their diagnostic imaging agents in Japan. This will help company to expand their business in the market.

Europe Iodinated Contrast Media in Interventional X-Ray Market Scope

The Europe iodinated contrast media in interventional X-Ray market is segmented on the basis of route of administration, indication, agent type, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Route of Administration

• Intravenous
• Oral
• Rectal
• Others

Indication

• Cardiology
• Neurology
• General Surgery
• Oncology
• Urology

Agent Type

• Non-Ionic
• Ionic

End User

• Hospital/Clinical Laboratories
• Physician Offices
• Reference Laboratories
• Others

Distribution Channel

• Direct Tender
• Retail Sales
• Other

 Europe Iodinated Contrast Media in Interventional X-Ray Market Regional Analysis/Insights

The Europe iodinated contrast media in interventional X-Ray market is analyzed and market size insights and trends are provided by route of administration, indication, agent type, end-user and distribution channel as referenced above.

The major countries covered in the Europe iodinated contrast media in interventional X-Ray market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

Europe iodinated contrast media in interventional X-ray market is increasing because of awareness about interventional diagnosis and treatment of the chronic disease is anticipated to grow at the significant growth rate in the forecast period. Also, the increasing government initiatives to create the awareness about cancer and cardiac diagnosis, innovative contrast agent products being launched by numerous companies is projected to grow at the growth rate. Furthermore, advancements of interventional X-ray technique and wide presence of leading companies in the region have also created new prospects for iodinated contrast media in interventional X-ray.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Europe Iodinated Contrast Media in Interventional X-Ray Market Share Analysis

The Europe iodinated contrast media in interventional X-Ray market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Europe respiratory diagnostics market.

Key players operating in the Europe iodinated contrast media in interventional X-Ray market include:

• Bayer AG (Germany)
• Iso-Tex Diagnostics, Inc. (U.S.)
• Bracco Diagnostic Inc. (Italy)
• Novalek Pharmaceuticals Pvt. Ltd. (India)
• TAEJOON PHARM (South Korea)
• Unijules Life Sciences Ltd (India)
• General Electric (U.S.)
• Guerbet (France)
• J.B.Pharma (India)

SKU-50698